Galenea license Organix 5-HT2C agonists

Galenea have licensed Organix’s 5-HT2C agonists for the treatment of obesity and other related disorders.

Progenics and Ono to Codevelop Relistor in Japan

Ono have signed an agreement to license Relistor (methylnaltrexone bromide) from Progenics for development in Japan

Merck and Japan Tobacco collaborate on Calcium Sensing Receptor antagonist

Merck have partnered with Japan Tobacco to commercialize JTT-305, a Ca sensing receptor antagonist with potential in the treatment of osteoporosis

Almirall receive $15M milestone from Forest for aclidinium bromide

Almirall has received a 15 million dollar payment from Forest Laboratories in connection with its phase III development of aclidinium bromide, an antimuscarinic for the treatment of COPD (Chronic Obstructive Pulmonary Disease).

Euroscreen sign agreement with Phoenix for Chemerin and F2L products

Euroscreen has signed an agreement with Phoenix Pharmaceuticals giving access to Chemerin and F2L patent rights. Financial details of this Agreement were not disclosed.

Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients

Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160724/TD-4208 to be safe and well tolerated in the treatment of chronic obstructive pulmonary disease (COPD). Partner GSK have, however, informed Theravance that it intends to return the LAMA program to Theravance because the current formulation of TD-4208 is incompatible with GSK’s [...]

Shire to acquire Jerini adding Bradykinin antagonist Icatibant to portfolio

Shire has proposed the acquisition of biotechnology company Jerini AG with which it will acquire hereditary angioedema product, Icatibant (Firazyr). Icatibant is a peptide Bradykinin B2 receptor antagonist

Senetek terminate license agreement with Ardana for Invicorp

Senetek have terminated a license agreement with Ardana for Invicorp due to Ardana’s entry into voluntary administration on June 27, 2008.

Procter & Gamble Ends Collaboration on ATI-7505

Procter & Gamble has ended its collaboration with ARYx Therapeutics for development and commercialization of 5-HT4 agonist ATI-7505 for chronic constipation and functional dyspepsia.

Sciele license Addrenex Alpha2 adrenoceptor agonist ADX415

Sciele Pharma has signed an agreement to license Addrenex Pharmaceuticals alpha 2 agonist ADX415 for the Treatment of Hypertension.